Status:
TERMINATED
Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance
Lead Sponsor:
Laval University
Conditions:
Dyspnea
Lung Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The main purpose of this study is to evaluate the effects of automated oxygen administration (FreeO2 system) alone or with high-flow oxygen on dyspnea and exercise tolerance in people with desaturatin...
Eligibility Criteria
Inclusion
- One of them
- Moderate to severe COPD (forced expiratory volume in 1 second (FEV1) \< 80% predicted and FEV1/forced vital capacity (FVC) ratio \< 0.7)
- Chronic interstitial lung disease such as usual interstitial pneumonitis (UIP), non-specific interstitial pneumonitis (NSIP) or hypersensitivity pneumonitis on high-resolution computed tomography
- Pulmonary arterial hypertension type 1 or 4, excluding involvement secondary to collagenosis as well as secondary to congenital heart disease, as diagnosed with mean pulmonary artery pressure \> 25 mm Hg at right heart catheterization
- Cystic fibrosis, as diagnosed by a positive sweat test (\>60 mmol/L) or having 2 genetic mutations known to cause cystic fibrosis.
- AND having a 6-minute walking test with significant desaturation defined as a decrease in O2 saturation greater or equal to 5% with O2 saturation at the end of the walking test \< 88%
Exclusion
- Exacerbation of the primary lung disease in the past 8 weeks
- Exercise limiting diseases other than the primary lung disease.
- Not reaching the target dyspnea score during the walking tests.
- Stage 1 pulmonary sarcoidosis
- History of syncope on exertion
- SpO2 with effort less than 90% despite the use of 6 L of O2 per minute
- Cardiac condition deemed unstable or severe (e.g. severe aortic stenosis)
- Disabling or severe rheumatological or neurological condition
- Participation in a pulmonary rehabilitation program within the last year
- Patients with multi-resistant bacteria
Key Trial Info
Start Date :
February 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05267418
Start Date
February 26 2019
End Date
March 30 2021
Last Update
March 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec, Canada, G1V4G5